AstraZeneca AZN reported disappointing results from two late-stage studies that evaluated its investigational light chain ...

AstraZeneca on Wednesday said that its experimental therapy anselamimab did not meet the main goal of a late-stage study for ...

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials. A ...

AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare ...

Carpal tunnel syndrome was linked to wild-type transthyretin amyloidosis in new research, highlighting the importance of ...

The global cardiac amyloidosis market is poised for substantial growth, driven by rising prevalence and awareness of amyloidosis-related cardiac conditions. Characterized by amyloid protein deposition ...

A new AI model accurately detected cardiac amyloidosis from echocardiograms with higher accuracy vs. other amyloidosis risk ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in ...

Amyloidosis is a group of conditions that cause an abnormal protein called amyloid to build up in the body. Treatment depends on the type of amyloidosis but may include medications and organ ...

So, amyloidosis, there are several types, several causes, and several symptoms, so you need a comprehensive team to get together and put this puzzle together. Interviewer: Yeah, and we have a clinic ...

Amyloidosis, a systemic disease that manifests in various ways, should be in the differential diagnosis of unexplained proteinuria, restrictive cardiomyopathy, peripheral and autonomic neuropathy, ...

Amyloidosis is a rare and possibly life-threatening disease affecting an estimated 4,000 people per year in the US. If left untreated, the disease can cause severe organ damage, so early detection is ...